Skip to main content
SpringerLink
Log in

Antidiabetika

  • Chapter
Arzneiverordnungs-Report 2008

  • 549 Accesses

Zusammenfassung

Die Arzneitherapie des Diabetes mellitus hat in den letzten zehn Jahren stetig zugenommen. Die Insulinverordnungen haben sich in diesem Zeitraum verdoppelt. Die Biguanidverordnungen sind mehr als dreifach angestiegen, während die der Sulfonylharnstoffe nach einem leichten Rückgang wieder etwas aufstreben. Glitazone (Rosiglitazon, Pioglitazon) zeigen nur noch verhaltene Zuwachsraten, da neuere Studien Hinweise auf ein erhöhtes Herzinfarkt- und Frakturrisiko gezeigt haben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Arzneimittelkommission der deutschen Ärzteschaft (2002): Empfehlungen zur Therapie des Diabetes mellitus Typ 2. AVP-Sonderheft Therapieempfehlungen, 1. Auflage. Internet: www.akdae.de/35/85_Diabetes_2002_1Auflage.pdf

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2004): Akutes Lungenödem durch Pioglitazon (Actos®). Dtsch Ärztebl 101: A3218.

    Google Scholar 

  • Bailey CJ, Path MRC, Turner RC (1996): Metformin. N Engl J Med 334: 574–579.

    Article  CAS  PubMed  Google Scholar 

  • Berger M, Köbberling J, Windeler J (1996): Wirksamkeit und Wertigkeit der Acarbose. Dtsch Ärztebl 93: B-443–B-444.

    Google Scholar 

  • Black C, Donnelly P, McIntyre L, Royle P, Shepherd J, Thomas S (2007): Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007 Apr 18; (2):CD004654.

    Google Scholar 

  • Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW et al. (1994): The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 121: 928–935.

    CAS  PubMed  Google Scholar 

  • Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M for the STOP-NIDDM Trail Research Group (2002): Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359: 2072–2077.

    Article  CAS  PubMed  Google Scholar 

  • Damsbo P, Clausen P, Marbury TC, Windfeld K (1999): A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 22: 789–794.

    Article  CAS  PubMed  Google Scholar 

  • De Fronzo RA, Goodman M (1995): Efficacy of metformin in patients with noninsulindependent diabetes mellitus. N Engl J Med 333: 541–549.

    Article  Google Scholar 

  • Diabetes Control and Complications Trial Research Group (1993): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986.

    Article  Google Scholar 

  • Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2005): Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643–2653.

    Article  Google Scholar 

  • Diamant M, Heine RJ (2003): Thiazolidinediones in type 2 diabetes mellitus. Drugs 63: 1373–1405.

    Article  CAS  PubMed  Google Scholar 

  • Dills DG, Schneider J (1996): Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 28: 426–429.

    Article  CAS  PubMed  Google Scholar 

  • Dormandy JA, Charbonnel B, Eckland DA, Erdmann E, Massi-Benedetti M et al. (2005): Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroV-ascular Events): a randomised controlled trial. Lancet 366: 1279–1289.

    Article  CAS  PubMed  Google Scholar 

  • Draeger KE, Wernicke-Panten K, Lomp H-J, Schüler E, Roßkamp R (1996): Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl®): a double-blind comparison with glibenclamide. Horm Metab Res 28: 419–425.

    Article  CAS  PubMed  Google Scholar 

  • Dunn CJ, Peters DH (1995): Metformin — A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49: 721–749.

    Article  CAS  PubMed  Google Scholar 

  • Fisman EZ, Tenenbaum A, Boyko V, Benderly M, Adler Y, Friedensohn A et al. (2001): Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 24: 151–158.

    Article  CAS  PubMed  Google Scholar 

  • Freemantie N (2005): How well does the evidence on pioglitazone back up researchers’ claims for a reduction in macrovascular events? BMJ 331: 836–838.

    Article  Google Scholar 

  • Gale EAM for the UK Trial Group (2000): A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. Diabetic Med 17: 209–214.

    Article  Google Scholar 

  • Gemeinsamer Bundesausschuss (2006): Medizinische Versorgung von Diabetes-Typ-2-Patienten gesichert. G-BA schützt Solidargemeinschaft vor überteuerten Pharmapreisen. Pressemitteilung vom 18.07.2006. Im Internet: www.g-ba.de/downloads/39-261-313Z2006-07-18-AMR-Insulinanaloga_BAnz.pdf

    Google Scholar 

  • Gulliford M, Latinovic R (2004): Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 20:239–245.

    Article  CAS  PubMed  Google Scholar 

  • Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M (2004): Acarbose reduziert das Risiko für einen Myocardinfarkt bei Typ 2 Diabetikern: Metaanalyse von sieben Langzeitstudien. European Heart Journal 25: 10–16.

    Article  CAS  PubMed  Google Scholar 

  • Hollander PA, Zheng H, Schwartz SL, Foley JE, Gatlin MR, Dunning BE, Haas SJ (2001): Importance of early insulin secretion. Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 24: 983–988.

    Article  CAS  PubMed  Google Scholar 

  • Holman RR, Mayon White V, Orde-Peckar C, Steemson J, Smith B et al. (1983): Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients: a two-year randomised prospective study. Lancet: 204–208.

    Google Scholar 

  • Holman RR, Cull CA, Turner RC (1999): A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 22: 960–964.

    Article  CAS  PubMed  Google Scholar 

  • Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ (2007): Rosiglitazone evaluated for cardiovascular outcomes — An interim analysis. N Engl J Med Jun 5; [Epub ahead of print].

    Google Scholar 

  • Institut für Wirtschaftlichkeit und Qualität im Gesundheitswesen (IQWiG) (2005): Kurzwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2. Abschlussbericht. Im Internet: www.iqwig.de/index.140.html

    Google Scholar 

  • Institut für Wirtschaftlichkeit und Qualität im Gesundheitswesen (IQWiG) (2008): Langwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2. Vorbericht. Im Internet: www.iqwig.de/download/A05-03_Vorbericht_Langwirksame_Insulinanaloga_zur_Behandlung_des_Diabetes_mellitus_Typ_2.pdf

    Google Scholar 

  • Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G; ADOPT Study Group (2006): Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427–1443.

    Article  CAS  PubMed  Google Scholar 

  • Karam JH, Etzwiler DD (eds.) (1983): International symposium on human insulin. Diabetes Care 6: 1–68.

    Google Scholar 

  • Keating GM (2005): Exenatide. Drugs 65: 1681–1692.

    Article  CAS  PubMed  Google Scholar 

  • Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group (2002): Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393–403.

    Article  CAS  PubMed  Google Scholar 

  • Landgraf R, Bilo HJ, Müller PG (1999): A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 55: 165–171.

    Article  CAS  PubMed  Google Scholar 

  • Landgraf R, Frank M, Bauer C, Dieken ML (2000): Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with type 2 diabetes. Int J Obes Relat Metab Disord 24(Suppl. 3): S38–44.

    PubMed  Google Scholar 

  • Laube H (2002): Acarbose. An update of its therapeutic use in diabetes treatment. Clin Drug Invest 22: 141–156.

    Article  CAS  Google Scholar 

  • Lyseng-Williamson KA (2007): Sitagliptin. Drugs 67: 587–597.

    Article  CAS  PubMed  Google Scholar 

  • Marbury T, Huang WC, Strange P, Lebovitz H (1999): Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res. Clin. Pract. 43: 155–166.

    Article  CAS  PubMed  Google Scholar 

  • McCall AL (2001): Clinical review of glimepiride. Expert Opin Pharmacother 2: 699–713.

    Article  CAS  PubMed  Google Scholar 

  • Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR (2008): Use of thiazolidinediones and fracture risk. Arch Intern Med 168: 820–825.

    Article  CAS  PubMed  Google Scholar 

  • Moses R (2000): A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes. Expert Opin Pharmacother 1: 1455–1467.

    Article  CAS  PubMed  Google Scholar 

  • Nathan DM (2006): Thiazolidinediones for initial treatment of type 2 diabetes? N Engl J Med 355: 2477–2480.

    Article  CAS  PubMed  Google Scholar 

  • Nissen SE, Wolski K (2007): Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. Engl J Med 356: 2457–2471.

    Article  CAS  Google Scholar 

  • Olsson J, Lindberg G, Gottsater M, Lindwall K, Sjostrand A et al. (2000): Increased mortality in type 2 diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 43: 558–560.

    Article  CAS  PubMed  Google Scholar 

  • Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group (2005): The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142: 611–619.

    CAS  PubMed  Google Scholar 

  • Psaty BM, Furberg CD (2007): Rosiglitazone and cardiovascular risk. N Engl J Med 356: 2522–2524.

    Article  CAS  PubMed  Google Scholar 

  • Scheen AJ (2003): Is there a role for alpha-Glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 63: 933–951.

    Article  CAS  PubMed  Google Scholar 

  • Scheen AJ, Lethiexhe MR, Lefèbvre PJ (1999): Minimal influence of the time interval between injection of regular insulin and food intake on blood glucose control of Type 1 diabetic patients on a basal-bolus insulin scheme. Diabetes Metab 25: 157–162.

    CAS  PubMed  Google Scholar 

  • Siebenhofer A, Plank J, Berghold A, Narath M, Gfrerer R, Pieber TR (2004): Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2004 Oct 18; (4):CD003287.

    Google Scholar 

  • Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE et al. (2000): Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Brit Med J 321: 405–412.

    Article  CAS  PubMed  Google Scholar 

  • Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE (1995): Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333: 550–554.

    Article  CAS  PubMed  Google Scholar 

  • Takeda Pharma (2007): Wichtige Sicherheitsinformation zu Frakturen unter Pioglitazon-Einnahme. Internet: www.akdae.de/20/40/Archiv/2007/54-20070402.pdf

    Google Scholar 

  • Tewes A, Frank M, Tegtbur U, Brinkmeier U (2006): Insulinpflichtiger Typ-2-Diabetes: Patientenzentrierte Schulung verbessert die Stoffwechsellage. Dtsch Ärztebl 103: A341–A345.

    Google Scholar 

  • The Action to Control Cardiovascular Risk in Diabetes Study Group (2008): Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545–2559.

    Article  Google Scholar 

  • The ADVANCE Collaborative Group (2008): Intensive blood glucose control and vas cular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560–2572.

    Article  Google Scholar 

  • The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators (2006): Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368: 1096–1105.

    Article  Google Scholar 

  • The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2005): Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643–2653.

    Article  Google Scholar 

  • Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H et al. for the Finnish Diabetes Prevention Study Group (2001): Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343–1350.

    Article  CAS  PubMed  Google Scholar 

  • Tuomilehto J, Wareham N (2006): Glucose lowering and diabetes prevention: are they the same? Lancet 368: 1218–1219.

    Article  PubMed  Google Scholar 

  • UK Prospective Diabetes Study (UKPDS) Group (1998a): Intensive glood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853.

    Article  Google Scholar 

  • UK Prospective Diabetes Study (UKPDS) Group (1998b): Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–865.

    Article  Google Scholar 

  • Veneman TF, Tack CJ, van Haeften TW (1998): The newly developed sulfonylurea glimepiride: a new ingredient, an old recipe. Neth J Med 52: 179–186.

    Article  CAS  PubMed  Google Scholar 

  • Warren E, Weatherley-Jones E, Chilcott J, Beverley C (2004): Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 8: 1–57.

    CAS  Google Scholar 

  • Wilde MI, McTavish D (1997): Insulin Lispro. A review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 54: 597–614.

    Article  CAS  PubMed  Google Scholar 

  • Wolffenbuttel BHR, Landgraf R on behalf of the Dutch and German Repaglinide Study Group (1999): A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Diabetes Care 22: 463–467.

    Article  CAS  PubMed  Google Scholar 

  • Yki-Jarvinen H (2005): The PROactive study: some answers, many questions. Lancet 366: 1241–1242.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Höferstraße 15, 68199, Mannheim

    Dr. med. Klaus Mengel

Authors
  1. Dr. med. Klaus Mengel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Die Gesundheitskasse, AOK Schleswig-Holstein, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Mengel, K. (2008). Antidiabetika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2008. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69219-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-69219-5_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-69218-8

  • Online ISBN: 978-3-540-69219-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation